Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 263

Sort by

Sort Order Select

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes

Blood (2024) 143 (17): 1752–1757.

https://doi.org/10.1182/blood.2023022180

Published: 2024

Includes: Supplemental data

Journal Articles

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Côme Bommier, Emanuele Zucca, Sylvie Chevret, Annarita Conconi, Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Catherine Thieblemont, Jérôme Lambert

Blood (2024) 143 (5): 422–428.

https://doi.org/10.1182/blood.2023020984

Published: 2024

Includes: Supplemental data

Journal Articles

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma

Côme Bommier, Brian K. Link, Brianna Gysbers, Matthew J. Maurer, Melissa C. Larson, Arushi Khurana, Yucai Wang, Carrie Thompson, Dai Chihara, Juan Pablo Alderuccio, Jean L. Koff, Izidore S. Lossos, Grzegorz S. Nowakowski, Andrew L. Feldman, Thomas M. Habermann, Rebecca L. King, James R. Cerhan

Blood (2023) 142 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2023-186626

Published: 2023

Journal Articles

Truncating SPEN Mutations Highlight BN2-Subtype DLBCL with Aggressive Biology and Features of Immune Evasion

Blood (2023) 142 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2023-181974

Published: 2023

Journal Articles

PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Blood (2023) 142 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2023-179478

Published: 2023

Journal Articles

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Blood (2023) 142 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2023-179303

Published: 2023

Journal Articles

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Blood (2023) 142 (Supplement 1): 847.

https://doi.org/10.1182/blood-2023-186969

Published: 2023

Journal Articles

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Côme Bommier, Mazie Tsang, Brie N. Noble, Carrie Thompson, Christopher Strouse, Carla Casulo, Eric Mou, Melissa C. Larson, Brianna Gysbers, Allison C. Rosenthal, Andrew L. Feldman, Matthew J. Maurer, Kathleen Yost, Susan L. Slager, Brian K. Link, Thomas M. Habermann, Amylou Constance Dueck, James R. Cerhan

Blood (2023) 142 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2023-186862

Published: 2023

Journal Articles

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Blood (2023) 142 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2023-182266

Published: 2023

Journal Articles

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Raphael Mwangi, Grzegorz S. Nowakowski, Carla Casulo, Dai Chihara, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Peter Martin, Yucai Wang, Timothy J. McDonnell, Andrew L. Feldman, David L Jaye, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2023-174715

Published: 2023

Journal Articles

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Amber Koehler, Brie N. Noble, Timothy G. Call, Sameer A. Parikh, Tait D. Shanafelt, Mazie Tsang, Côme Bommier, Kari G. Rabe, Christopher Strouse, Carrie Thompson, Paul J. Hampel, Kathleen Yost, Melissa C. Larson, Susan L. Slager, Brian K. Link, James R. Cerhan, Amylou Constance Dueck

Blood (2023) 142 (Supplement 1): 498.

https://doi.org/10.1182/blood-2023-187268

Published: 2023

Journal Articles

DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma

Melissa A. Hopper, Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, Miranda S. Laverty, Michelle Manske, Xiaosheng Wu, Kerstin Wenzl, Jordan Edward Krull, Vivekananda Sarangi, Matthew J. Maurer, Thomas M. Habermann, Brian K. Link, Lisa M. Rimsza, Thomas E. Witzig, Stephen M Ansell, James R. Cerhan, Dragan Jevremovic, Anne J. Novak

Blood (2023) 142 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2023-180232

Published: 2023

Journal Articles

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Blood (2023) 142 (Supplement 1): 2770.

https://doi.org/10.1182/blood-2023-180949

Published: 2023

Journal Articles

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

Jonathan R Day, Melissa C. Larson, Carla Casulo, Urshila Durani, Yucai Wang, Dai Chihara, Loretta J. Nastoupil, Brad S. Kahl, Peter Martin, Izidore S. Lossos, Jason T. Romancik, Amy Ayers, Richard Burack, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Brian K. Link

Blood (2023) 142 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2023-179650

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2023-186684

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Blood (2023) 142 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2023-187056

Published: 2023

Journal Articles

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Rosalie Griffin, Aswin Sekar, Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, Nicholas J. Boddicker, Paul J. Hampel, Neil E. Kay, Timothy G. Call, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Caline M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager

Blood (2023) 142 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2023-184696

Published: 2023

NARROW

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma

Truncating SPEN Mutations Highlight BN2-Subtype DLBCL with Aggressive Biology and Features of Immune Evasion

PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only